S
Sequenta
Biotech & Life Sciences · Oyster Point, United States · Founded 2008
Biotech company developing immune-driven clinical products for personalized disease diagnosis and treatment MoreLess
Sequenta is a commercial-stage biotech company focused on harnessing the adaptive immune system to transform the diagnosis and treatment of diseases. The company operates in the life sciences research, clinical diagnostics, and drug discovery markets. Sequenta's proprietary immune medicine platform decodes the genetics of the adaptive immune system with unprecedented scale, precision, and speed, enabling the development of personalized clinical products. The company serves healthcare providers, research institutions, and pharmaceutical companies. Sequenta generates revenue through the commercialization of its diagnostic and therapeutic products, as well as partnerships with industry leaders. Keywords: biotech, immune system, diagnostics, therapeutics, personalized medicine, life sciences, clinical products, drug discovery, healthcare, precision health.
Company overview
Sequenta company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2008
- Headquarters
- Oyster Point, United States
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 60.8
Valuation & funding
Sequenta funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Jan 2015 | $0 | — | Adaptive Biotechnologies | — |
| EARLY VC✓Equity / VC | Oct 2014 | $0 | — | Celgene | — |
| SERIES C✓Equity / VC | Jul 2013 | $20M | $80M | Foresite Capital · Index Ventures · Mohr Davidow Ventures | — |
| EARLY VC✓Equity / VC | Jan 2012 | $8.5M | $34M | Mohr Davidow Ventures · Index Ventures · Farzad (Zod) Nazem | — |
| SERIES B✓Equity / VC | Dec 2010 | $13M | $52M | Mohr Davidow Ventures · Index Ventures · Farzad (Zod) Nazem | — |
| EARLY VC✓Equity / VC | Jul 2009 | Undisclosed | — |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 1 |
Growth signals
Sequenta website traffic
Latest recorded traffic for Sequenta is 290 monthly website visits.
Comparisons
Sequenta compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Sequenta's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Sequenta has talent and traffic
team presence
In the news
Latest news about Sequenta
Recent press, funding announcements, and product moves mentioning Sequenta — open to read from the original sources.
Market sentiment
What the market is saying about Sequenta
An AI-synthesized read of the highest-engagement posts about Sequenta on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sequenta’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.